CD133+ tumor initiating cells in a syngenic murine model of pancreatic cancer respond to minnelide

Sulagna Banerjee, Alice Nomura, Veena Sangwan, Rohit Chugh, Vikas Dudeja, Selwyn M. Vickers, Ashok Saluja

Research output: Contribution to journalArticle

35 Citations (Scopus)

Abstract

Purpose: Pancreatic adenocarcinoma is the fourth leading cause for cancer-related mortality with a survival rate of less than 5%. Late diagnosis and lack of effective chemotherapeutic regimen contribute to these grim survival statistics. Relapse of any tumor is largely attributed to the presence of tumor-initiating cells (TIC) or cancer stem cells (CSC). These cells are considered as hurdles to cancer therapy as no known chemotherapeutic compound is reported to target them. Thus, there is an urgent need to develop a TICtargeted therapy for pancreatic cancer. Experimental Design: Weisolated CD133+ cells from a spontaneous pancreatic ductal adenocarcinoma mouse model and studied both surface expression, molecular markers of pancreatic TICs. We also studied tumor initiation properties by implanting low numbers of CD133+ cells in immune competent mice. Effect of Minnelide, a drug currently under phase I clinical trial, was studied on the tumors derived from the CD133+ cells. Results: Our study showed for the first time that CD133+ population demonstrated all the molecular markers for pancreatic TIC. These cells initiated tumors in immunocompetent mouse models and showed increased expression of prosurvival and proinvasive proteins compared to the CD133-non-TIC population. Our study further showed that Minnelide was very efficient in downregulating both CD133-and CD133+ population in the tumors, resulting in a 60% decrease in tumor volume compared with the untreated ones. Conclusion: As Minnelide is currently under phase I clinical trial, its evaluation in reducing tumor burden by decreasing TIC as well as non-TIC population suggests its potential as an effective therapy.

Original languageEnglish (US)
Pages (from-to)2388-2399
Number of pages12
JournalClinical Cancer Research
Volume20
Issue number9
DOIs
StatePublished - May 1 2014
Externally publishedYes

Fingerprint

Neoplastic Stem Cells
Pancreatic Neoplasms
Neoplasms
Clinical Trials, Phase I
Tumor Burden
Population
Adenocarcinoma
Delayed Diagnosis
14-O-phosphonooxymethyltriptolide
Research Design
Therapeutics
Down-Regulation
Survival Rate
Cell Count
Recurrence
Mortality
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Medicine(all)

Cite this

CD133+ tumor initiating cells in a syngenic murine model of pancreatic cancer respond to minnelide. / Banerjee, Sulagna; Nomura, Alice; Sangwan, Veena; Chugh, Rohit; Dudeja, Vikas; Vickers, Selwyn M.; Saluja, Ashok.

In: Clinical Cancer Research, Vol. 20, No. 9, 01.05.2014, p. 2388-2399.

Research output: Contribution to journalArticle

Banerjee, Sulagna ; Nomura, Alice ; Sangwan, Veena ; Chugh, Rohit ; Dudeja, Vikas ; Vickers, Selwyn M. ; Saluja, Ashok. / CD133+ tumor initiating cells in a syngenic murine model of pancreatic cancer respond to minnelide. In: Clinical Cancer Research. 2014 ; Vol. 20, No. 9. pp. 2388-2399.
@article{3fef1c6cac2a444d9ab2aa9b110b5438,
title = "CD133+ tumor initiating cells in a syngenic murine model of pancreatic cancer respond to minnelide",
abstract = "Purpose: Pancreatic adenocarcinoma is the fourth leading cause for cancer-related mortality with a survival rate of less than 5{\%}. Late diagnosis and lack of effective chemotherapeutic regimen contribute to these grim survival statistics. Relapse of any tumor is largely attributed to the presence of tumor-initiating cells (TIC) or cancer stem cells (CSC). These cells are considered as hurdles to cancer therapy as no known chemotherapeutic compound is reported to target them. Thus, there is an urgent need to develop a TICtargeted therapy for pancreatic cancer. Experimental Design: Weisolated CD133+ cells from a spontaneous pancreatic ductal adenocarcinoma mouse model and studied both surface expression, molecular markers of pancreatic TICs. We also studied tumor initiation properties by implanting low numbers of CD133+ cells in immune competent mice. Effect of Minnelide, a drug currently under phase I clinical trial, was studied on the tumors derived from the CD133+ cells. Results: Our study showed for the first time that CD133+ population demonstrated all the molecular markers for pancreatic TIC. These cells initiated tumors in immunocompetent mouse models and showed increased expression of prosurvival and proinvasive proteins compared to the CD133-non-TIC population. Our study further showed that Minnelide was very efficient in downregulating both CD133-and CD133+ population in the tumors, resulting in a 60{\%} decrease in tumor volume compared with the untreated ones. Conclusion: As Minnelide is currently under phase I clinical trial, its evaluation in reducing tumor burden by decreasing TIC as well as non-TIC population suggests its potential as an effective therapy.",
author = "Sulagna Banerjee and Alice Nomura and Veena Sangwan and Rohit Chugh and Vikas Dudeja and Vickers, {Selwyn M.} and Ashok Saluja",
year = "2014",
month = "5",
day = "1",
doi = "10.1158/1078-0432.CCR-13-2947",
language = "English (US)",
volume = "20",
pages = "2388--2399",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "9",

}

TY - JOUR

T1 - CD133+ tumor initiating cells in a syngenic murine model of pancreatic cancer respond to minnelide

AU - Banerjee, Sulagna

AU - Nomura, Alice

AU - Sangwan, Veena

AU - Chugh, Rohit

AU - Dudeja, Vikas

AU - Vickers, Selwyn M.

AU - Saluja, Ashok

PY - 2014/5/1

Y1 - 2014/5/1

N2 - Purpose: Pancreatic adenocarcinoma is the fourth leading cause for cancer-related mortality with a survival rate of less than 5%. Late diagnosis and lack of effective chemotherapeutic regimen contribute to these grim survival statistics. Relapse of any tumor is largely attributed to the presence of tumor-initiating cells (TIC) or cancer stem cells (CSC). These cells are considered as hurdles to cancer therapy as no known chemotherapeutic compound is reported to target them. Thus, there is an urgent need to develop a TICtargeted therapy for pancreatic cancer. Experimental Design: Weisolated CD133+ cells from a spontaneous pancreatic ductal adenocarcinoma mouse model and studied both surface expression, molecular markers of pancreatic TICs. We also studied tumor initiation properties by implanting low numbers of CD133+ cells in immune competent mice. Effect of Minnelide, a drug currently under phase I clinical trial, was studied on the tumors derived from the CD133+ cells. Results: Our study showed for the first time that CD133+ population demonstrated all the molecular markers for pancreatic TIC. These cells initiated tumors in immunocompetent mouse models and showed increased expression of prosurvival and proinvasive proteins compared to the CD133-non-TIC population. Our study further showed that Minnelide was very efficient in downregulating both CD133-and CD133+ population in the tumors, resulting in a 60% decrease in tumor volume compared with the untreated ones. Conclusion: As Minnelide is currently under phase I clinical trial, its evaluation in reducing tumor burden by decreasing TIC as well as non-TIC population suggests its potential as an effective therapy.

AB - Purpose: Pancreatic adenocarcinoma is the fourth leading cause for cancer-related mortality with a survival rate of less than 5%. Late diagnosis and lack of effective chemotherapeutic regimen contribute to these grim survival statistics. Relapse of any tumor is largely attributed to the presence of tumor-initiating cells (TIC) or cancer stem cells (CSC). These cells are considered as hurdles to cancer therapy as no known chemotherapeutic compound is reported to target them. Thus, there is an urgent need to develop a TICtargeted therapy for pancreatic cancer. Experimental Design: Weisolated CD133+ cells from a spontaneous pancreatic ductal adenocarcinoma mouse model and studied both surface expression, molecular markers of pancreatic TICs. We also studied tumor initiation properties by implanting low numbers of CD133+ cells in immune competent mice. Effect of Minnelide, a drug currently under phase I clinical trial, was studied on the tumors derived from the CD133+ cells. Results: Our study showed for the first time that CD133+ population demonstrated all the molecular markers for pancreatic TIC. These cells initiated tumors in immunocompetent mouse models and showed increased expression of prosurvival and proinvasive proteins compared to the CD133-non-TIC population. Our study further showed that Minnelide was very efficient in downregulating both CD133-and CD133+ population in the tumors, resulting in a 60% decrease in tumor volume compared with the untreated ones. Conclusion: As Minnelide is currently under phase I clinical trial, its evaluation in reducing tumor burden by decreasing TIC as well as non-TIC population suggests its potential as an effective therapy.

UR - http://www.scopus.com/inward/record.url?scp=84899730785&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84899730785&partnerID=8YFLogxK

U2 - 10.1158/1078-0432.CCR-13-2947

DO - 10.1158/1078-0432.CCR-13-2947

M3 - Article

C2 - 24634377

AN - SCOPUS:84899730785

VL - 20

SP - 2388

EP - 2399

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 9

ER -